New Real-World Study Finds Long-Term XARELTO ® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news